The humoral response and antibodies against SARS-CoV-2 infection

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

(2022) Wanwisa Dejnirattisai et al.   CELL

Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron

(2022) Juan Manuel Carreño et al.   NATURE

Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization

(2022) Sandile Cele et al.   NATURE

Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa

(2022) Raquel Viana et al.   NATURE

Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants

(2022) Kang Wang et al.   NATURE

Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies

(2022) Yunlong Cao et al.   NATURE

Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2

(2022) Lihong Liu et al.   NATURE

An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies

(2022) Laura A. VanBlargan et al.   NATURE MEDICINE

Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial

(2022) Jingxin Li et al.   NATURE MEDICINE

Homologous and Heterologous Covid-19 Booster Vaccinations

(2022) Robert L. Atmar et al.   NEW ENGLAND JOURNAL OF MEDICINE

SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination

(2022) Rolando Pajon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Structures of the Omicron Spike trimer with ACE2 and an anti-Omicron antibody

(2022) Wanchao Yin et al.   SCIENCE

Circular RNA vaccines against SARS-CoV-2 and emerging variants

(2022) Liang Qu et al.   CELL

mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron

(2022) Matthew Gagne et al.   CELL

Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost

(2022) Frauke Muecksch et al.   NATURE

FcγR-mediated SARS-CoV-2 infection of monocytes activates inflammation

(2022) Caroline Junqueira et al.   NATURE

Targeted isolation of diverse human protective broadly neutralizing antibodies against SARS-like viruses

(2022) Wan-ting He et al.   NATURE IMMUNOLOGY

Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement

(2022) Matthew McCallum et al.   SCIENCE

Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529

(2022) Tongqing Zhou et al.   SCIENCE

LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants

(2022) Kathryn Westendorf et al.   Cell Reports

Evolution of antibody immunity to SARS-CoV-2

(2021) Christian Gaebler et al.   NATURE

Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody

(2021) C. Garrett Rappazzo et al.   SCIENCE

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

(2021) Jennifer M. Dan et al.   SCIENCE

Prospective mapping of viral mutations that escape antibodies used to treat COVID-19

(2021) Tyler N. Starr et al.   SCIENCE

Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry

(2021) Jiwan Ge et al.   Nature Communications

Maturation and persistence of the anti-SARS-CoV-2 memory B cell response

(2021) Aurélien Sokal et al.   CELL

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity

(2021) Wilfredo F. Garcia-Beltran et al.   CELL

Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection

(2021) Emma S. Winkler et al.   CELL

Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection

(2021) Elizabeth M. Anderson et al.   CELL

Potent SARS-CoV-2 Neutralizing Antibodies Directed Against Spike N-Terminal Domain Target a Single Supersite

(2021) Gabriele Cerutti et al.   Cell Host & Microbe

The Effect of Convalescent Plasma Therapy on COVID-19 Patient Mortality: Systematic Review and Meta-analysis

(2021) Stephen A. Klassen et al.   MAYO CLINIC PROCEEDINGS

Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7

(2021) Pengfei Wang et al.   NATURE

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

(2021) Zijun Wang et al.   NATURE

Prolonged evolution of the human B cell response to SARS-CoV-2 infection

(2021) Mrunal Sakharkar et al.   Science Immunology

Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein

(2021) Naveenchandra Suryadevara et al.   CELL

N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2

(2021) Matthew McCallum et al.   CELL

Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant

(2021) Carl Graham et al.   IMMUNITY

Profiling B cell immunodominance after SARS-CoV-2 infection reveals antibody evolution to non-neutralizing viral targets

(2021) Haley L. Dugan et al.   IMMUNITY

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

(2021) Obbina Abani et al.   LANCET

Diverse Functional Autoantibodies in Patients with COVID-19

(2021) Eric Y. Wang et al.   NATURE

Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses

(2021) Kevin O. Saunders et al.   NATURE

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

(2021) David S. Khoury et al.   NATURE MEDICINE

mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection

(2021) Leonidas Stamatatos et al.   SCIENCE

The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates

(2021) Bryan E. Jones et al.   Science Translational Medicine

A majority of uninfected adults show preexisting antibody reactivity against SARS-CoV-2

(2021) Abdelilah Majdoubi et al.   JCI Insight

In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies

(2021) Dapeng Li et al.   CELL

Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines

(2021) Alexandra C. Walls et al.   CELL

SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2

(2021) Fatima Amanat et al.   CELL

Safety and immunogenicity of a recombinant adenovirus type-5-vectored COVID-19 vaccine with a homologous prime-boost regimen in healthy participants aged 6 years and above: a randomised, double-blind, placebo-controlled, phase 2b trial

(2021) Fengcai Zhu et al.   CLINICAL INFECTIOUS DISEASES

Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations

(2021) Frauke Muecksch et al.   IMMUNITY

Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants

(2021) Saya Moriyama et al.   IMMUNITY

A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope

(2021) Laura A. VanBlargan et al.   IMMUNITY

Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species

(2021) Ruoke Wang et al.   IMMUNITY

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial

(2021) Xinxue Liu et al.   LANCET

Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy

(2021) Rachel Yamin et al.   NATURE

SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans

(2021) Jackson S. Turner et al.   NATURE

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

(2021) Delphine Planas et al.   NATURE

SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses

(2021) Jackson S. Turner et al.   NATURE

Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies

(2021) Florian A. Lempp et al.   NATURE

Broad sarbecovirus neutralization by a human monoclonal antibody

(2021) M. Alejandra Tortorici et al.   NATURE

Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection

(2021) Zijun Wang et al.   NATURE

Pan-Sarbecovirus Neutralizing Antibodies in BNT162b2-Immunized SARS-CoV-1 Survivors

(2021) Chee-Wah Tan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

(2021) Paul T. Heath et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants

(2021) Lingshu Wang et al.   SCIENCE

SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern

(2021) Matthew McCallum et al.   SCIENCE

Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study

(2021) Kathryn M. Hastie et al.   SCIENCE

Broad betacoronavirus neutralization by a stem helix–specific human antibody

(2021) Dora Pinto et al.   SCIENCE

The development and kinetics of functional antibody-dependent cell-mediated cytotoxicity (ADCC) to SARS-CoV-2 spike protein

(2021) Xuemin Chen et al.   VIROLOGY

Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies to human coronaviruses

(2021) Natalia Ortega et al.   Nature Communications

SARS-CoV-2 mucosal antibody development and persistence and their relation to viral load and COVID-19 symptoms

(2021) Janeri Fröberg et al.   Nature Communications

Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths

(2021) Paul Bastard et al.   Science Immunology

Recombinant protein subunit vaccine booster following two-dose inactivated vaccines dramatically enhanced anti-RBD responses and neutralizing titers against SARS-CoV-2 and Variants of Concern

(2021) Jingwen Ai et al.   CELL RESEARCH

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

(2021) Alasdair P S Munro et al.   LANCET

Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant

(2021) Jun Zhang et al.   SCIENCE

Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults

(2021) Ritthideach Yorsaeng et al.   VACCINE

SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity

(2021) M. Gordon Joyce et al.   Cell Reports

A Potent and Protective Human Neutralizing Antibody Against SARS-CoV-2 Variants

(2021) Sisi Shan et al.   Frontiers in Immunology

A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge

(2021) Kathryn McGuckin Wuertz et al.   npj Vaccines

SARS-CoV-2 infection generates tissue-localized immunological memory in humans

(2021) Maya M.L. Poon et al.   Science Immunology

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

(2020) Roujian Lu et al.   LANCET

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

(2020) Chaolin Huang et al.   LANCET

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

(2020) Daniel Wrapp et al.   SCIENCE

Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody

(2020) Xiaolong Tian et al.   Emerging Microbes & Infections

Autopsy Findings and Venous Thromboembolism in Patients With COVID-19

(2020) Dominic Wichmann et al.   ANNALS OF INTERNAL MEDICINE

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

(2020) Daniel Blanco-Melo et al.   CELL

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

(2020) Alba Grifoni et al.   CELL

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

(2020) Alexandra C. Walls et al.   CELL

Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure

(2020) Evangelos J. Giamarellos-Bourboulis et al.   Cell Host & Microbe

Clinical and immunological features of severe and moderate coronavirus disease 2019

(2020) Guang Chen et al.   JOURNAL OF CLINICAL INVESTIGATION

A human neutralizing antibody targets the receptor binding site of SARS-CoV-2

(2020) Rui Shi et al.   NATURE

Human neutralizing antibodies elicited by SARS-CoV-2 infection

(2020) Bin Ju et al.   NATURE

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

(2020) Dora Pinto et al.   NATURE

Respiratory disease in rhesus macaques inoculated with SARS-CoV-2

(2020) Vincent J. Munster et al.   NATURE

Antibody responses to SARS-CoV-2 in patients with COVID-19

(2020) Quan-Xin Long et al.   NATURE MEDICINE

The Prevalence of Olfactory and Gustatory Dysfunction in COVID-19 Patients: A Systematic Review and Meta-analysis

(2020) Jane Y. Tong et al.   OTOLARYNGOLOGY-HEAD AND NECK SURGERY

A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2

(2020) Yan Wu et al.   SCIENCE

SARS-CoV-2 infection protects against rechallenge in rhesus macaques

(2020) Abishek Chandrashekar et al.   SCIENCE

A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV

(2020) Meng Yuan et al.   SCIENCE

B Cell Activation and Response Regulation During Viral Infections

(2020) Jonathan H. Lam et al.   VIRAL IMMUNOLOGY

COVID-19 cytokine storm: the interplay between inflammation and coagulation

(2020) Ricardo J Jose et al.   Lancet Respiratory Medicine

Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies

(2020) Christopher O. Barnes et al.   CELL

Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells

(2020) Yunlong Cao et al.   CELL

Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike

(2020) Jiandong Huo et al.   Cell Host & Microbe

Longitudinal dynamics of the neutralizing antibody response to SARS-CoV-2 infection

(2020) Kai Wang et al.   CLINICAL INFECTIOUS DISEASES

Cytokine Storms: Understanding COVID-19

(2020) Nilam Mangalmurti et al.   IMMUNITY

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

(2020) Feng-Cai Zhu et al.   LANCET

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

(2020) Davide F. Robbiani et al.   NATURE

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

(2020) Lihong Liu et al.   NATURE

Potently neutralizing and protective human antibodies against SARS-CoV-2

(2020) Seth J. Zost et al.   NATURE

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

(2020) Quan-Xin Long et al.   NATURE MEDICINE

Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient

(2020) Daming Zhou et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2

(2020) Xiangyang Chi et al.   SCIENCE

Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications

(2020) Divij Mathew et al.   SCIENCE

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

(2020) Jérôme Hadjadj et al.   SCIENCE

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail

(2020) Johanna Hansen et al.   SCIENCE

Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody

(2020) Zhe Lv et al.   SCIENCE

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

(2020) Philip J. M. Brouwer et al.   SCIENCE

Broad neutralization of SARS-related viruses by human monoclonal antibodies

(2020) Anna Z. Wec et al.   SCIENCE

Structural basis of a shared antibody response to SARS-CoV-2

(2020) Meng Yuan et al.   SCIENCE

Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans

(2020) Jose Mateus et al.   SCIENCE

Comprehensive mapping of immune perturbations associated with severe COVID-19

(2020) Leticia Kuri-Cervantes et al.   Science Immunology

The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients

(2020) Lakshmanane Premkumar et al.   Science Immunology

COVID-19: unravelling the clinical progression of nature’s virtually perfect biological weapon

(2020) Giuseppe Lippi et al.   Annals of Translational Medicine

Deficiency of Tfh Cells and Germinal Center in Deceased COVID-19 Patients

(2020) Ya-qi Duan et al.   Current Medical Science

Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies

(2020) Meng Yuan et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Convalescent plasma therapy for B-cell depleted patients with protracted COVID-19 disease

(2020) Thomas Hueso et al.   BLOOD

A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model

(2020) Jakob Kreye et al.   CELL

Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19

(2020) Takuya Sekine et al.   CELL

Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19

(2020) Naoki Kaneko et al.   CELL

Molecular Architecture of the SARS-CoV-2 Virus

(2020) Hangping Yao et al.   CELL

Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy

(2020) Shuo Du et al.   CELL

Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology

(2020) Luca Piccoli et al.   CELL

SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies

(2020) Christopher O. Barnes et al.   NATURE

Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19

(2020) Matthew C. Woodruff et al.   NATURE IMMUNOLOGY

Characteristics of SARS-CoV-2 and COVID-19

(2020) Ben Hu et al.   NATURE REVIEWS MICROBIOLOGY

HLA and immunological features of SARS-CoV-2-induced Guillain-Barré syndrome

(2020) Gian Luigi Gigli et al.   NEUROLOGICAL SCIENCES

Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity

(2020) Ellen Shrock et al.   SCIENCE

Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms

(2020) M. Alejandra Tortorici et al.   SCIENCE

Autoantibodies against type I IFNs in patients with life-threatening COVID-19

(2020) Paul Bastard et al.   SCIENCE

Virology, transmission, and pathogenesis of SARS-CoV-2

(2020) Muge Cevik et al.   BMJ-British Medical Journal

An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain

(2020) Nicholas C. Wu et al.   Cell Reports

Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies

(2020) Wen Shi Lee et al.   Nature Microbiology

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

(2020) Jeffrey Seow et al.   Nature Microbiology

Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals

(2020) Yuanmei Zhu et al.   Science Advances

Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production

(2020) Yuezhou Chen et al.   CELL

COVID-19 and autoimmune diseases

(2020) Yu Liu et al.   CURRENT OPINION IN RHEUMATOLOGY

Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity

(2020) Hejun Liu et al.   IMMUNITY

Germinal Center and Extrafollicular B Cell Responses in Vaccination, Immunity, and Autoimmunity

(2020) Rebecca A. Elsner et al.   IMMUNITY

High prevalence of pre-existing serological cross-reactivity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in sub-Saharan Africa

(2020) For Yue Tso et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo

(2020) Alexandra Schäfer et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison

(2020) Ioanna-Evdokia Galani et al.   NATURE IMMUNOLOGY

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

(2020) Lindsey R. Baden et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Enhanced SARS-CoV-2 neutralization by dimeric IgA

(2020) Zijun Wang et al.   Science Translational Medicine

IgA dominates the early neutralizing antibody response to SARS-CoV-2

(2020) Delphine Sterlin et al.   Science Translational Medicine

Clinical manifestations of COVID-19 in the general population: systematic review

(2020) Rodrigo da Rosa Mesquita et al.   WIENER KLINISCHE WOCHENSCHRIFT

Mucosal Immunity in COVID-19: A Neglected but Critical Aspect of SARS-CoV-2 Infection

(2020) Michael W. Russell et al.   Frontiers in Immunology

Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19

(2020) Carlo Cervia et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Remembrance of Things Past: Long-Term B Cell Memory After Infection and Vaccination

(2019) Anna-Karin E. Palm et al.   Frontiers in Immunology

Divergent Roles of Antiself Antibodies during Infection

(2018) Juan Rivera-Correa et al.   TRENDS IN IMMUNOLOGY